Tiziana Executive Chairman Raises Stake to 34.93%
Tiziana Life Sciences’ Executive Chairman Gabriele Cerrone has quietly increased his stake to 34.93% via Panetta Partners, purchasing 42,357 shares at $0.99, signaling strong insider confidence in the clinical-stage biotech’s lead asset intranasal foralumab. The move could bolster governance, financing, and partnership prospects as the company advances its MS-focused immunomodulation programs.
Business · 5 sources · Jul 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Foralumab
Foralumab (TZLS-401), being researched by Tiziana Life Sciences) is a fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex. It is currently being studied in a randomized, double-blind placebo-controlled, multicenter dose-ranging study in a nasal formulation in patients with non-active secondary progressive multiple sclerosis (SPMS).
Everything about Foralumab →